Doxycycline and airway inflammation in COPD A randomised placebo controlled cross-over trial in patients with GOLD III COPD

Doxycycline and airway inflammation in COPD A randomised placebo controlled cross-over trial in patients with GOLD III COPD - Doxycycline and airway inflammation in COPD

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

NL-OMON

Registry ID

NL-OMON31738

Enrollment

Registered

2008-04-15

Start date

2008-06-01

Completion date

Unknown

Last updated

2024-05-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COPD lung emphysema

Interventions

Doxycycline vs placebo

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: • GOLD II COPD (FEV1/FVC 40 yrs. • Written informed consent.

Exclusion criteria

Exclusion criteria: • Infections and/or use of antibiotics in the last month. • Allergy for tetracyclines or a history of substantial side-effects. • Active respiratory diseases other than COPD (e.g. sarcoidosis, tuberculosis, lung cancer, bronchiectasis). • Signs and/or symptoms consistent with an acute exacerbation of COPD (AECOPD), such as increase in dyspnea, increase in sputum volume or change of sputum color from mucoid to purulent. • Signs and/or symptoms of a current respiratory or non-respiratory infection. • Use of oral or intravenous corticosteroids or other immunosuppressive drugs within the last month.

Design outcomes

Primary

Measure	Time frame
Change in sputum IL-6 levels	—

Secondary

Measure	Time frame
Change in FEV1 Change in markers of neutrophil activation/activity (IL-8, MMP-8, MMP-9 and MPO), T cell activation (granzyme A and perforin) and monocyte activation (TNF-a, IL-1, cathepsin K	—

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)